Valuation: Clarity Pharmaceuticals Ltd

Market Cap 58Cr 41Cr 37Cr 34Cr 31Cr 57Cr 3.86TCr 404.1Cr 160.49Cr 2.02TCr 152.67Cr 149.4Cr 6.42TCr P/E 2027 *
-4.89x
P/E 2028 * -5.82x
Enterprise Value 51Cr 36Cr 32Cr 30Cr 27Cr 51Cr 3.44TCr 359.38Cr 142.73Cr 1.8TCr 135.77Cr 132.87Cr 5.71TCr EV / Sales 2027 *
-
EV / Sales 2028 * 14.9x
Free-Float
78.88%
Yield 2027 *
-
Yield 2028 * -
1 day-1.59%
1 week-13.41%
Current month-26.19%
1 month-26.54%
3 months-34.04%
6 months-47.28%
Current year-54.14%
1 week 1.52
Extreme 1.515
1.8
1 month 1.52
Extreme 1.515
2.15
Current year 1.52
Extreme 1.515
4.26
1 year 1.52
Extreme 1.515
5.14
3 years 1
Extreme 1
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap. Importance
22/04/26 Sell

Chief Executive Officer

3,60,896 0.0969%
28/11/25 Free

Chief Operating Officer

1,99,909 0.0537%
28/11/25 Free

Chief Operating Officer

2,87,530 0.0773%
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-13.41%-65.63%+55.00% 41Cr
-3.10%-3.43%+36.29%+67.69% 6.53TCr
+0.33%+0.33%+10.16%+78.07% 5.46TCr
+0.16%+1.73%+9.89%+102.10% 5.36TCr
-0.76%+1.74%+25.34%+51.45% 4.5TCr
-1.32%-4.73%+16.13%+114.91% 4.22TCr
+1.28%-5.36%+220.78%+899.57% 3.94TCr
-0.74%-4.84%+14.53%+44.45% 3.27TCr
-2.70%-7.34%+23.17%+0.36% 2.4TCr
+1.11%+15.18%+60.27%+49.33% 2.65TCr
Average -0.71%+0.54%+35.09%+146.29% 3.84TCr
Weighted average by Cap. -0.69%+1.70%+43.21%+155.24%

Financials

2027 *2028 *
Net sales - 3.3Cr 2.32Cr 2.09Cr 1.93Cr 1.75Cr 3.26Cr 220.68Cr 23Cr 9.17Cr 115.67Cr 8.72Cr 8.53Cr 366.82Cr
Net income -12Cr -8.49Cr -7.62Cr -7.04Cr -6.38Cr -12Cr -806.35Cr -84Cr -33Cr -422.66Cr -32Cr -31Cr -1.34TCr -10Cr -7.11Cr -6.38Cr -5.89Cr -5.34Cr -9.98Cr -675.24Cr -71Cr -28Cr -353.94Cr -27Cr -26Cr -1.12TCr
Net Debt -6.4Cr -4.5Cr -4.04Cr -3.73Cr -3.38Cr -6.32Cr -427.56Cr -45Cr -18Cr -224.11Cr -17Cr -17Cr -710.68Cr -8.7Cr -6.12Cr -5.49Cr -5.07Cr -4.6Cr -8.59Cr -581.21Cr -61Cr -24Cr -304.65Cr -23Cr -22Cr -966.09Cr
Projected Income Statement - Annual - Clarity Pharmaceuticals Ltd
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
100
Date Price Change Volume
27/26/27 A$1.550 -1.59% 37,14,069
26/26/26 A$1.575 +0.32% 36,15,863
23/26/23 A$1.570 -6.27% 51,80,808
22/26/22 A$1.675 -5.90% 36,56,198
21/26/21 A$1.780 +0.56% 22,98,386
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Clarity Pharmaceuticals Ltd
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.550AUD
Average target price
7.195AUD
Spread / Average Target
+364.19%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Clarity Pharmaceuticals Ltd